Core Viewpoint - Kanghong Pharmaceutical has shown a positive stock performance with a year-to-date increase of 13.65% and a market capitalization of 31.38 billion yuan as of January 9 [1]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical achieved a revenue of 3.624 billion yuan, representing a year-on-year growth of 6.23%. The net profit attributable to shareholders was 1.033 billion yuan, with a year-on-year increase of 6.08% [2]. Shareholder Information - As of December 31, the number of shareholders for Kanghong Pharmaceutical reached 28,900, an increase of 1.32% from the previous period. The average number of circulating shares per shareholder decreased by 1.30% to 23,805 shares [2]. Dividend Distribution - Since its A-share listing, Kanghong Pharmaceutical has distributed a total of 2.038 billion yuan in dividends, with 1.04 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 28.007 million shares, an increase of 730,000 shares from the previous period. Other notable shareholders include Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A, which saw reductions in their holdings [3].

证券日报网讯 1月8日，康弘药业发布公告称，公司于2025年12月3日召开第八届董事会第十四次会议、 2025年12月19日召开二〇二五年第一次临时股东会审议通过了《关于变更公司注册资本及修订〈公司章 程〉的议案》。公司于近日完成了公司章程的相关工商变更登记手续。 （文章来源：证券日报） ...

证券代码：002773 证券简称：康弘药业 公告编号：2026-002 成都康弘药业集团股份有限公司 关于完成工商变更登记及公司章程修订的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 12 月 3 日召开第八届董事会第十四次会议、2025 年 12 月 19 日召 开二〇二五年第一次临时股东会审议通过了《关于变更公司注册资本 及修订〈公司章程〉的议案》，具体详见公司于 2025 年 12 月 4 日、 2025 年 12 月 20 日在《证券时报》《中国证券报》《上海证券报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）披露的《第八届 董事会第十四次会议决议公告》（公告编号：2025-064）和《关于变 更公司注册资本及修订<公司章程>的公告》（公告编号：2025-065）、 《二〇二五年第一次临时股东会决议公告》（公告编号：2025-070）。 公司于近日完成了公司章程的相关工商变更登记手续。 一、《公司章程》修订的具体情况 | 序号 | 修订前 第一条 为维护公司、 ...

证券日报网讯1月8日，康弘药业（002773）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东户数为28852户。 ...

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. announced that its subsidiary, Chengdu Hongji Biotechnology Co., Ltd., received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug KH631, which is intended for the treatment of Diabetic Macular Edema (DME) [1][4]. Group 1: Drug Information - The drug KH631 is an eye injection developed by Hongji Biotechnology, classified as a Class 1 therapeutic biological product [2]. - The drug has received clinical trial approval in China on November 15, 2022, and in the United States on November 22, 2022, for the treatment of Neovascular (Wet) Age-related Macular Degeneration (nAMD) [2]. - KH631 utilizes a proprietary Adeno-Associated Virus (AAV) delivery system, showcasing unique characteristics in tissue specificity, immunogenicity, controllable expression, and infection efficiency, with demonstrated sustained efficacy in preclinical disease models [2]. Group 2: Impact on the Company - The company acknowledges that the drug development process, including clinical trials, reviews, and approvals, carries inherent uncertainties, urging investors to make cautious decisions and be aware of investment risks [3].

Group 1 - The core point of the article highlights that in December 2025, the worst-performing ordinary equity and mixed funds were both managed by Baoying Fund, specifically the Baoying Medical Health Hong Kong-Shenzhen Stock A and C, which reported returns of -13.20% and -13.26% respectively [1] - The Baoying Innovation Medical Mixed Initiation A and C funds also performed poorly, with returns of -14.14% and -14.19%, making them the worst in the mixed fund category [1] - All these funds are themed around the medical sector and are managed by the same fund manager, Yao Yi, who has a background in research and fund management [1] Group 2 - The latest quarterly report indicates that the top ten holdings of the Baoying Medical Health Hong Kong-Shenzhen Stock fund include major companies such as Innovent Biologics, Kelun Pharmaceutical, and others, while the Baoying Innovation Medical Mixed Initiation fund shares many of the same top holdings [1][2] - Notably, several of these top holdings experienced significant declines in December, with the largest holding, Innovent Biologics, dropping by 18.97%, and another major holding, 3SBio, declining by over 22% [2] - The performance metrics of the funds show that the Baoying Innovation Medical Mixed Initiation C has a cumulative net value of 0.8857 and a scale of 0.51 billion, while the A share has a cumulative net value of 0.8886 and a scale of 0.47 billion [3]

1月6日，康弘药业盘中上涨2.06%，截至09:39，报33.65元/股，成交1.47亿元，换手率0.64%，总市值 310.02亿元。 资金流向方面，主力资金净流出1138.40万元，特大单买入935.76万元，占比6.35%，卖出1724.08万元， 占比11.70%；大单买入2640.18万元，占比17.92%，卖出2990.27万元，占比20.29%。 康弘药业今年以来股价涨12.28%，近5个交易日涨9.40%，近20日涨8.48%，近60日跌6.55%。 康弘药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、眼科概 念、生物医药、阿尔茨海默、医疗器械等。 截至12月19日，康弘药业股东户数2.85万，较上期增加1.28%；人均流通股24118股，较上期减少 1.26%。2025年1月-9月，康弘药业实现营业收入36.24亿元，同比增长6.23%；归母净利润10.33亿元，同 比增长6.08%。 分红方面，康弘药业A股上市后累计派现20.38亿元。近三年，累计派现10.40亿元。 机构持仓方面，截止2025年9月30日，康弘药业十大流通股东中，香港中央结算有限公司位居第 ...

从资金流向上来看，当日生物制品板块主力资金净流入1.91亿元，游资资金净流出2.73亿元，散户资金净 流入8203.94万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002773 康弘药业 | | 1.18 Z | 18.31% | -3021.77万 | -4.70% | -8748.13万 | -13.61% | | 000661 | 长春高新 | 7444.34万 | 9.43% | -4755.38万 | -6.02% | -2688.95万 | -3.40% | | 688331 荣昌生物 | | 6982.31万 | 10.14% | -2366.87万 | -3.44% | -4615.43万 | -6.71% | | 300122 智飞生物 | | 3724.35万 | 9.83% | 85.58万 | 0.23% | -3809.93万 | -10.05% ...

Group 1 - Kanghong Pharmaceutical's subsidiary Chengdu Hongji Biotechnology Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of KH631 eye injection, aimed at treating diabetic macular edema (DME) [1] Group 2 - Nepean Mining Machine has received approval from the China Securities Regulatory Commission for the registration of a convertible bond issuance to unspecified investors [2] - Tianqi Co., Ltd.'s controlling shareholder Huang Weixing has released 4 million shares from pledge, which represents 0.99% of the company's total share capital [2] - Huang Weixing and his concerted parties have a total of 8.9848 million pledged shares maturing in the next six months, accounting for 2.23% of the total share capital, and 29.59 million shares maturing within a year, representing 7.36% of the total share capital [2]